Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: An open-label, randomized study

BMC Pulmonary Medicine

Volumn 11, Issue , 2011, Pages

  Bodzenta Lukaszyk, Anna ^a   Dymek, Andrzej ^b   McAulay, Kirsten ^c   Mansikka, Heikki ^c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Medical Center Lucyna Andrzej Dymek   (Poland)

^c Mundipharma Research Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTIFORM; SALBUTAMOL; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUTICASONE; FLUTICASONE, SALMETEROL DRUG COMBINATION; FORMOTEROL; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; ASTHMA; BRAIN HEMORRHAGE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEART ARREST; HUMAN; INFECTION; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MAXIMAL EXPIRATORY FLOW; OPEN STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIA; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; QUALITY OF LIFE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79956205897     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-11-28     Document Type: Article

References (31)

1. Masoli M, Fabian D, Holt S, Beasley R. Global burden of asthma, a report for the Global Initiative for Asthma. 2004, http://www.ginasthma.org
2. Dean BB, Calimlim BM, Kindermann SL, Khandker RK, Tinkelman D. The impact of uncontrolled asthma on absenteeism and health-related quality of life. J Asthma 2009, 46:861-866. 10.3109/02770900903184237, 19905909.
3. Bahadori K, Doyle-Waters M, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. BMC Pulm Med 2009, 9:24. 10.1186/1471-2466-9-24, 2698859, 19454036.
4. Demoly P, Gueron B, Annunziata K, Adamek L, Walters RD. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev 2010, 19:150-157. 10.1183/09059180.00002110, 20956184.
5. Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, Accordini S, Almar E, Bugiani M, Carolei A, et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007, 120:1360-1367. 10.1016/j.jaci.2007.09.019, 17981317.
6. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996, 9:636-642. 10.1183/09031936.96.09040636, 8726924.
7. Accordini S, Bugiani M, Arossa W, Gerzeli S, Marinoni A, Olivieri M, Pirina P, Carrozzi L, Dallari R, De Togni A, de Marco R. Poor control increases the economic cost of asthma. Int Arch Allergy Immunol 2006, 141:189-198. 10.1159/000094898, 16899987.
8. Partidge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006, 6:13. 10.1186/1471-2466-6-13, 1483837, 16772035.
9. Braido F, Baiardini I, Stagi E, Piroddi MG, Balestracci S, Canonica GW. Unsatisfactory asthma control: astonishing evidence from general practitioners and respiratory medicine specialists. J Investig Allergol Clin Immunol 2010, 20:9-12.
10. Howell G. Nonadherence to medical therapy in asthma: risk factors, barriers, and strategies for improving. J Asthma 2008, 45:723-729. 10.1080/02770900802395512, 18972285.
11. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007, 29:587-595. 10.1183/09031936.00080306, 17329493.
12. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004, 113:245-51. 10.1016/j.jaci.2003.10.011, 14767437.
13. Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI, O'Connor BJ. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma. J Allergy Clin Immunol 2002, 110:603-606. 10.1067/mai.2002.128486, 12373268.
14. Luijk B, Kempsford RD, Wright AM, Zanen P, Lammers J-WJ. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J 2004, 23:559-564. 10.1183/09031936.04.00043504, 15083754.
15. Pearlman DS, Peden D, Condemi JJ, Weinstein S, White M, Baitinger L, Scott C, Ho SY, House K, Dorinsky P. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma 2004, 41:797-806. 10.1081/JAS-200038368, 15641629.
16. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999, 13:988-992. 10.1034/j.1399-3003.1999.13e10.x, 10414394.
17. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981, 123:659-664.
18. Marks GB, Dunn SM, Woolcock AJ. An evaluation of an asthma quality of life questionnaire as a measure of change in adults with asthma. J Clin Epidemiol 1993, 46:1103-1111. 10.1016/0895-4356(93)90109-E, 8410095.
19. Wei L, Lin D, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Statistical Assoc 1989, 84:1065-1073.
20. GINA report. Global strategy for asthma management and prevention. 2009, http://www.ginasthma.org
21. Adams NP, Bestall JC, Jones P, Lasserson TJ, Griffiths B, Cates CJ. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2009, (2):CD003534.
22. Adams NP, Lasserson TJ, Cates CJ, Jones P. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2009, (2):CD002310.
23. Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrancois G. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration 2005, 72(Suppl 1):6-12.
24. Edwards SJ, Gruffydd-Jones K, Ryan DP. Systematic review and meta-analysis of budesonide/formoterol in a single inhaler. Curr Med Res Opin 2007, 23:1809-1820. 10.1185/030079907X210697, 17597557.
25. Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009, 103:41-49. 10.1016/j.rmed.2008.09.002, 18977646.
26. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999, 160:244-249.
27. Bodzenta-Lukaszyk A, Pulka G, Dymek A, Bumbacea D, McIver T, Schwab B, Mansikka H. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir Med 2011, 105:674-682.
28. Harding G, Leidy NK, Meddis D, Kleinman L, Wagner S, O'Brien CD. Interpreting clinical trial results of patient-perceived onset of effect in asthma: methods and results of a Delphi panel. Curr Med Res Opin 2009, 25:1563-1571. 10.1185/03007990902914403, 19445651.
29. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009, 10:37-45. 10.1186/1745-6215-10-37, 2700087, 19493350.
30. Hauber AB, Mohamed AF, Johnson FR, Meddis D, Wagner S, O'Dowd L. Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta2-agonist maintenance medications. Allergy Asthma Proc 2009, 30:139-147. 10.2500/aap.2009.30.3205, 19463204, 19463204.
31. Karanicolas PJ, Montori VM, Devereaux PJ, Schunemann H, Guyatt GH. A new 'mechanistic-practical' framework for designing and interpreting randomized trials. J Clin Epidemiol 2009, 62:479-484. 10.1016/j.jclinepi.2008.02.009, 18468856.